At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months post-dosing at. | June 16, 2023
Autolus Therapeutics (AUTL) Reports Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SALT LAKE CITY, April 13, 2021 /PRNewswire/ ARUP Laboratories today announced the retirement of CEO Sherrie L. Perkins, MD, PhD, effective June 30, 2021. ARUP also announced that Andy Theurer, currently ARUP s president, has been appointed by the company s Board of Directors to become CEO with Perkins retirement.
Tracy George, MD, will replace Theurer as president and will retain her current position as ARUP s chief medical officer (CMO). I am very grateful to Sherrie Perkins for her exceptional leadership as CEO and for her many other extraordinary contributions to ARUP and the University of Utah School of Medicine, said Peter E. Jensen, MD, chairman of the ARUP Board of Directors and of the U School of Medicine Department of Pathology. She has demonstrated a true commitment to ARUP and the work we do that has such an impact on patients and on our clients nationwide. She will be sorely missed.